SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be
evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside
analogues from stavudine (d4T) to tenofovir treatment and after 4.
Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and
mitochondrial function at 48 weeks.